Bionano Genomics Announces the Appointment of Stephanie Hoyle as VP Corporate Marketing and Alex Helm as VP Strategic Product Marketing
November 04 2021 - 8:00AM
Bionano Genomics, Inc. (BNGO), developer of the Saphyr® system
that uses optical genome mapping (OGM) for the detection and
analysis of structural variants (SVs), today announced that two
former Illumina executives, Stephanie Hoyle and Alex Helm, have
joined the Company as vice presidents of Corporate Marketing and
Strategic Product Marketing, respectively. Together, they bring 22
years of experience in the genomics space and 36 years of
experience in marketing.
At Bionano, Stephanie will oversee global marketing and brand
strategy for the Company. During her tenure at Illumina, she worked
in similar positions and was instrumental in developing the brand
and marketing strategy for the Reproductive and Genetic Health
Business Unit, and most recently, was the global head of Brand
Programs, leading the corporate rebrand for the business unit.
After leaving Illumina, Stephanie founded the Hoyle Marketing
Group. She worked with numerous life sciences companies on brand
and marketing strategy, including BioLegend, ChromaCode, CodexDNA,
Fortis Life Sciences, Rady’s Children’s Institute for Genomic
Medicine and Verogen.
Alex will be responsible for developing the long-term, global
product roadmap and portfolio strategy for Bionano’s set of
products and service solutions to influence the Company’s annual
strategic planning process. Previously, he was director of Regional
Marketing for the Americas at Illumina and responsible for clinical
segments including oncology, genetic disease and infectious disease
testing and reproductive health. As the global lead for Illumina’s
Reproductive and Genetic Health Business Unit, Alex oversaw a
critical product launch for the IVD-marked VeriSeq NIPT Solution,
which significantly broadened access to safer prenatal screening
for families around the world.
“I am thrilled that Stephanie and Alex have joined our team to
lead our brand evolution and strategic product marketing planning,”
said Erik Holmlin, PhD, CEO of Bionano Genomics. “By providing
better product solutions for our customers, our goal is to elevate
human health and ultimately create better outcomes for
patients.”
About Bionano Genomics
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through optical genome
mapping (OGM) solutions, diagnostic services and software. The
Company offers OGM solutions for applications across basic,
translational and clinical research. Through its Lineagen business,
the Company also provides diagnostic testing for patients with
clinical presentations consistent with autism spectrum disorder and
other neurodevelopmental disabilities. Through its BioDiscovery
business, the Company also offers an industry-leading,
platform-agnostic software solution, which integrates
next-generation sequencing and microarray data designed to provide
analysis, visualization, interpretation and reporting of copy
number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com, www.lineagen.com or
www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) convey uncertainty of future events or outcomes and
are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: the impact of the
expansion of our marketing leadership team, including our
expectations regarding the growth of
Saphyr® and our ability to bolster customer
experience globally. Each of these forward-looking statements
involves risks and uncertainties. Actual results or developments
may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with: the
impact of the COVID-19 pandemic on our business and the global
economy; general market conditions; changes in the competitive
landscape and the introduction of competitive products; our hiring
efforts may not achieve the anticipated results; changes in our
strategic and commercial plans; our ability to obtain sufficient
financing to fund our strategic plans and commercialization
efforts; the ability of medical and research institutions to obtain
funding to support adoption or continued use of our technologies;
the loss of key members of management and our commercial team; and
the risks and uncertainties associated with our business and
financial condition in general, including the risks and
uncertainties described in our filings with the Securities and
Exchange Commission, including, without limitation, our Annual
Report on Form 10-K for the year ended December 31, 2020 and in
other filings subsequently made by us with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics,
Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1 (858)
366-3243amy@juniper-point.com
Media Relations:Michael SullivanSeismic+1 (503)
799-7520michael@teamseismic.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024